Showing 661-670 of 21412 results for "".
- AMT-191 Phase I/IIa Update: Durable α‑Gal A, Hepatic Signals, and Nephrology Implicationshttps://reachmd.com/news/amt-191-phase-iiia-update-durable-gal-a-hepatic-signals-and-nephrology-implications/2485605/Preliminary open-label data from the
- Exploring Social Determinants of Health and Treatment Disparities in Stage I Lung Cancer: Insights from Ontariohttps://reachmd.com/news/exploring-social-determinants-of-health-and-treatment-disparities-in-stage-i-lung-cancer-insights-from-ontario/2484983/An Ontario population-based cohort shows material deprivation is linked to lower receipt of surgical resection and greater reliance on radiotherapy or no treatment among adults with early-stage lung cancer, as reported in the
- Ethris Doses First Patient with Antiviral mRNA Drug in Phase I Asthma Trialhttps://reachmd.com/news/ethris-doses-first-patient-with-antiviral-mrna-drug-in-phase-i-asthma-trial/2463243/
- EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2https://reachmd.com/news/edta-chelation-no-help-in-cutting-cv-outcomes-after-mi-in-diabetic-patients-tact2/2462631/ATLANTA, GA—More than a decade after the TACT trial reported an astonishing reduction in cardiovascular events post-MI with heavy metal chelation in a subset of diabetic patients, the TACT2 trial, designed to test edetate disodium (EDTA) solely in a diabetic popu
- A New Biomarker Helps Detect Kidney Fibrosis in Transplant Patients Without Invasive Procedureshttps://reachmd.com/news/a-new-biomarker-helps-detect-kidney-fibrosis-in-transplant-patients-without-invasive-procedures/2468714/by Germans Trias i Pujol Research Institute
- MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Studyhttps://reachmd.com/news/mira-pharmaceuticals-achieves-100-reversal-of-neuropathic-pain-with-oral-ketamir-2-in-breakthrough-study/2468049/Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pha
- Surgical Therapy and Glycemic Outcomes in Diabetic Gastroparesishttps://reachmd.com/news/surgical-therapy-and-glycemic-outcomes-in-diabetic-gastroparesis/2487295/Key Takeaways HbA1c declined in the surgical cohort and rose in the nonoperative cohort over follow-up. Among patients eligible for each analysis, severe hyperglycemia and new fast-acting and long-acting insulin use were less common in the surgical coh
- Produce Prescription Subsidy in Diabetes: Pragmatic Trial Resultshttps://reachmd.com/news/produce-prescription-subsidy-in-diabetes-pragmatic-trial-results/2487092/Key Takeaways At 12 months, the produce prescription subsidy was not associated with better glycemic outcomes than usual care. No between-group differences were reported in emergency department visits, blood pressure, body mass index, or inpatient visi
- Revolutionizing Pediatric Diabetes Care: The Role of Tirzepatidehttps://reachmd.com/news/revolutionizing-pediatric-diabetes-care-the-role-of-tirzepatide/2483463/As incretin-based therapies advance, clinicians are weighing early pediatric data on tirzepatide against established standards of care that prioritize metformin and insulin in youth, with limited use of GLP-1 receptor agonists. Within that context, tirzepatide—an emerging option in
- Unlocking New Pathways: Cabergoline’s Role in Diabetes Managementhttps://reachmd.com/news/unlocking-new-pathways-cabergolines-role-in-diabetes-management/2482990/Central to the scientific interest in cabergoline is the hypothesis that it may influence glucose control via dopamine D2-like receptor agonism, a concept supported by preliminary evidence discussed in a mechanistic review. Building on that framework,